Diabetic Macular Edema News and Research

RSS

Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.

Preclinical data of Ocugen's OCU400 genetic modifier published in Nature Gene Therapy

Ocugen, Inc., a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced today the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases.

3 Mar 2020

Helper protein exacerbates diabetic macular edema

In a recent study using mice, lab-grown human retinal cells and patient samples, Johns Hopkins Medicine scientists say they found evidence of a new pathway that may contribute to degeneration of the light sensitive tissue at the back of the eye.

27 Nov 2019

Retinal macular damage linked to sleep apnea in diabetes

A new Taiwanese study presented on October 14, 2019, at the Annual Meeting of the American Academy of Ophthalmology, reports that macular edema in diabetes occurs more often in those who have severe sleep apnea.

15 Oct 2019

Sleep apnea is a risk factor for developing diabetic macular edema, study shows

New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes that can cause vision loss or blindness. Diabetic macular edema was also more difficult to treat in patients with severe sleep apnea.

14 Oct 2019

Inflammasome, Boehringer Ingelheim team up to develop new therapies for retinal diseases

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases.

From Boehringer Ingelheim International GmbH 25 Sep 2019

HbA1c analyzer identifies diabetics with poor glycemic control and high risk of sight loss

This HbA1c analyzer is successfully supporting improved medical management of patients with sight-threatening diabetic retinopathy (STDR).

From EKF Diagnostics 16 Jul 2019

A new strategy for managing diabetic macular edema in people with good vision

A change to the approach for treating diabetic macular edema may be on the way, thanks to a study published today in the Journal of the American Medical Association.

2 May 2019

Experimental drug may be twice as good at fighting vision loss as previously thought

In studies with lab-grown human cells and in mice, Johns Hopkins Medicine researchers have found that an experimental drug may be twice as good at fighting vision loss as previously thought.

11 Apr 2019

New cellular atlas could provide a deeper insight into blinding diseases

When it comes to understanding how neurons connect to form circuits in the brain, scientists for decades have turned to the retina of the humble laboratory mouse as an ideal model organism. But as a model for vision and vision-related diseases, mice simply aren't equipped.

22 Feb 2019

Researchers use AI to diagnose diabetes-related eye disease

Researchers have used artificial intelligence to support the instant diagnosis of one of the top causes of blindness, diabetes-related eye disease, in its earliest stages.

8 Jan 2019

RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders

RetiPharma has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute to develop a new drug for degenerative eye disorders.

From Novo Nordisk 15 Nov 2018

TGen-UNM consortium awarded NIH grant to discover new treatments for diabetic blindness

Diabetes is an increasing global epidemic that is expected to grow by more than 50 percent in the next two decades, leaving more than half a billion patients worldwide exposed to potentially life-altering medical complications, including pain and numbness in the feet, lost limbs, life-threatening disorders of the heart, liver and kidneys -- and even blindness.

26 Sep 2018

Largest clinical specialty database powers studies that yield key insights

The American Academy of Ophthalmology today announced key milestones and clinical insights from studies powered by its clinical database.

13 Nov 2017

New micro-pump technology may offer promising alternative to eye drops for glaucoma patients

It is no secret that the issues associated with current glaucoma medications can be problematic. Systemic medications carry the risk of side effects, while the current medical treatment of choice, eye drops, has its own drawbacks.

2 Mar 2017

Red color channel can help detect diabetic macular edema in racial/ethnic minority patients

In photographs of the eye used to screen for diabetes-related eye disease, separating out the red color channel can help show some abnormalities—especially in racial/ethnic minority patients, suggests a study in the February issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

6 Feb 2017

Joslin scientists suggest new approach to improve stroke therapy

The standard of care for treating strokes caused by blood clots involves the therapeutic infusion of tissue plasminogen activator (tPA), which can help to dissolve the clots and restore blood flow.

27 Jan 2017

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR).

13 Jan 2016

New study reveals better treatment options for proliferative diabetic retinopathy

This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes.

20 Nov 2015

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment.

17 Nov 2015

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA.

15 Nov 2015